Lantheus (LNTH) Stock Forecast, Price Target & Predictions
LNTH Stock Forecast
Lantheus stock forecast is as follows: an average price target of $146.25 (represents a 69.17% upside from LNTH’s last price of $86.45) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
LNTH Price Target
The average price target for Lantheus (LNTH) is $146.25 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $175.00 to $120.00. This represents a potential 69.17% upside from LNTH's last price of $86.45.
LNTH Analyst Ratings
According to 6 Wall Street analysts, Lantheus's rating consensus is 'Buy'. The analyst rating breakdown for LNTH stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Lantheus Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 03, 2024 | Ed Ridley-Day | Redburn Partners | $175.00 | $106.47 | 64.37% | 102.43% |
| Aug 01, 2024 | David Turkaly | JMP Securities | $125.00 | $104.83 | 19.24% | 44.59% |
| Jul 12, 2024 | Anthony Petrone | Mizuho Securities | $165.00 | $123.62 | 33.47% | 90.86% |
| Nov 15, 2022 | - | Leerink Partners | $120.00 | $57.25 | 109.61% | 38.81% |
| Aug 05, 2022 | - | Leerink Partners | $110.00 | $76.25 | 44.26% | 27.24% |
The latest Lantheus stock forecast, released on Sep 03, 2024 by Ed Ridley-Day from Redburn Partners, set a price target of $175.00, which represents a 64.37% increase from the stock price at the time of the forecast ($106.47), and a 102.43% increase from LNTH last price ($86.45).
Lantheus Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 3 |
| Avg Price Target | - | $175.00 | $155.00 |
| Last Closing Price | $86.45 | $86.45 | $86.45 |
| Upside/Downside | -100.00% | 102.43% | 79.29% |
In the current month, the average price target of Lantheus stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Lantheus's last price of $86.45. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 16, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 01, 2024 | JMP Securities | Outperform | Outperform | Hold |
| Jul 25, 2024 | B. Riley | Buy | Buy | Hold |
| Jul 10, 2024 | JMP Securities | Outperform | Outperform | Hold |
| May 03, 2024 | Truist Financial | Market Outperform | Market Outperform | Hold |
| May 03, 2024 | Mizuho Securities | Underperform | Underperform | Hold |
| Apr 18, 2024 | B. Riley | Buy | Buy | Hold |
| Feb 23, 2024 | Cowen & Co. | Underperform | Underperform | Hold |
| Feb 23, 2024 | JMP Securities | Market Outperform | Market Outperform | Hold |
| Nov 15, 2022 | SVB Leerink | Outperform | Outperform | Hold |
Lantheus's last stock rating was published by Cowen & Co. on Sep 16, 2024. The company gave LNTH a "Buy" rating, the same as its previous rate.
Lantheus Financial Forecast
Lantheus Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $319.95M | $321.70M | $300.78M | $263.17M | $239.29M | $223.72M | $208.88M | $129.56M | $102.07M | $101.06M | $92.51M | $94.15M | $88.54M |
| Avg Forecast | $544.58M | $513.23M | $481.60M | $450.90M | $438.56M | $429.29M | $424.34M | $412.93M | $405.90M | $394.11M | $394.07M | $380.35M | $376.63M | $371.29M | $382.12M | $349.25M | $339.56M | $314.26M | $305.78M | $280.68M | $244.74M | $228.01M | $204.40M | $165.30M | $111.78M | $97.13M | $94.77M | $87.24M | $92.23M | $91.96M |
| High Forecast | $557.23M | $525.16M | $492.79M | $461.38M | $448.74M | $439.27M | $434.20M | $422.52M | $415.33M | $403.27M | $403.23M | $380.84M | $389.26M | $371.87M | $382.12M | $349.25M | $343.01M | $319.28M | $312.89M | $287.20M | $250.43M | $228.01M | $204.40M | $165.30M | $111.78M | $97.13M | $94.77M | $87.24M | $92.23M | $91.96M |
| Low Forecast | $535.20M | $504.39M | $473.30M | $443.13M | $431.00M | $421.90M | $417.03M | $405.81M | $398.91M | $387.32M | $387.28M | $379.86M | $365.96M | $370.70M | $382.12M | $349.25M | $324.60M | $311.98M | $300.51M | $275.85M | $240.52M | $228.01M | $204.40M | $165.30M | $111.78M | $97.13M | $94.77M | $87.24M | $92.23M | $91.96M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 8 | 4 | 3 | 3 | 6 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 8 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 1.05% | 1.07% | 1.08% | 1.05% | 1.09% | 1.26% | 1.16% | 1.05% | 1.07% | 1.06% | 1.02% | 0.96% |
Lantheus's average Quarter revenue forecast for Dec 23 based on 6 analysts is $339.56M, with a low forecast of $324.60M, and a high forecast of $343.01M. LNTH's average Quarter revenue forecast represents a 6.13% increase compared to the company's last Quarter revenue of $319.95M (Sep 23).
Lantheus EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 8 | 4 | 3 | 3 | 6 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 8 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $112.36M | $143.93M | $-6.11M | $-173.07M | $98.40M | $75.35M | $70.72M | $-27.28M | $-5.93M | $-16.97M | $25.18M | $8.36M | $3.88M |
| Avg Forecast | $69.10M | $65.12M | $61.11M | $57.22M | $55.65M | $54.47M | $53.84M | $52.40M | $51.51M | $50.01M | $50.00M | $48.26M | $47.79M | $47.11M | $48.49M | $65.80M | $43.09M | $39.88M | $38.80M | $59.82M | $-17.47M | $14.05M | $12.60M | $63.98M | $6.89M | $5.99M | $5.84M | $5.38M | $5.69M | $5.67M |
| High Forecast | $70.71M | $66.64M | $62.53M | $58.54M | $56.94M | $55.74M | $55.10M | $53.61M | $52.70M | $51.17M | $51.17M | $48.33M | $49.39M | $47.19M | $48.49M | $78.96M | $43.53M | $40.51M | $39.70M | $71.78M | $-13.98M | $14.05M | $12.60M | $76.77M | $6.89M | $5.99M | $5.84M | $5.38M | $5.69M | $5.67M |
| Low Forecast | $67.91M | $64.00M | $60.06M | $56.23M | $54.69M | $53.53M | $52.92M | $51.49M | $50.62M | $49.15M | $49.14M | $48.20M | $46.44M | $47.04M | $48.49M | $52.64M | $41.19M | $39.59M | $38.13M | $47.86M | $-20.97M | $14.05M | $12.60M | $51.18M | $6.89M | $5.99M | $5.84M | $5.38M | $5.69M | $5.67M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.82% | 3.71% | -0.10% | 9.90% | 7.00% | 5.98% | 1.11% | -3.96% | -0.99% | -2.91% | 4.68% | 1.47% | 0.68% |
6 analysts predict LNTH's average Quarter EBITDA for Dec 23 to be $43.09M, with a high of $43.53M and a low of $41.19M. This is -61.65% lower than Lantheus's previous annual EBITDA (Sep 23) of $112.36M.
Lantheus Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 8 | 4 | 3 | 3 | 6 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 8 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $131.96M | $94.13M | $-2.81M | $-119.19M | $61.23M | $43.06M | $42.96M | $-40.22M | $-13.41M | $-26.66M | $9.01M | $-3.41M | $-6.39M |
| Avg Forecast | $156.17M | $148.31M | $138.59M | $129.16M | $143.94M | $140.28M | $140.28M | $134.44M | $143.42M | $117.63M | $122.00M | $113.20M | $111.94M | $113.72M | $133.68M | $39.71M | $104.56M | $96.67M | $95.68M | $36.10M | $-25.76M | $58.66M | $49.63M | $38.61M | $11.77M | $4.47M | $3.49M | $56.75M | $841.21K | $-4.10M |
| High Forecast | $160.89M | $152.79M | $142.77M | $133.07M | $148.28M | $144.52M | $144.52M | $138.50M | $147.75M | $121.19M | $125.69M | $114.63M | $119.16M | $114.58M | $133.69M | $47.65M | $112.33M | $98.87M | $99.97M | $43.32M | $-20.61M | $58.66M | $49.63M | $46.33M | $11.77M | $4.47M | $3.49M | $68.10M | $841.21K | $-4.10M |
| Low Forecast | $152.67M | $144.99M | $135.49M | $126.27M | $140.71M | $137.14M | $137.14M | $131.43M | $140.21M | $115.00M | $119.27M | $111.07M | $107.61M | $112.85M | $133.67M | $31.77M | $97.49M | $92.28M | $91.40M | $28.88M | $-30.91M | $58.66M | $49.63M | $30.89M | $11.77M | $4.47M | $3.49M | $45.40M | $841.21K | $-4.10M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.37% | 0.98% | -0.08% | 4.63% | 1.04% | 0.87% | 1.11% | -3.42% | -3.00% | -7.64% | 0.16% | -4.06% | 1.56% |
Lantheus's average Quarter net income forecast for Dec 23 is $104.56M, with a range of $97.49M to $112.33M. LNTH's average Quarter net income forecast represents a -20.76% decrease compared to the company's last Quarter net income of $131.96M (Sep 23).
Lantheus SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 8 | 4 | 3 | 3 | 6 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 8 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $73.14M | $62.61M | $55.89M | $66.62M | $49.17M | $60.09M | $57.94M | $81.95M | $45.74M | $60.81M | $30.31M | $26.54M | $29.83M |
| Avg Forecast | $173.43M | $163.44M | $153.37M | $143.59M | $139.66M | $136.71M | $135.14M | $131.50M | $129.26M | $125.51M | $125.50M | $121.13M | $119.94M | $118.24M | $121.69M | $53.55M | $108.14M | $100.08M | $97.38M | $48.68M | $52.50M | $72.61M | $65.09M | $52.07M | $35.60M | $30.93M | $30.18M | $27.78M | $29.37M | $29.28M |
| High Forecast | $177.46M | $167.24M | $156.93M | $146.93M | $142.91M | $139.89M | $138.27M | $134.56M | $132.27M | $128.42M | $128.41M | $121.28M | $123.96M | $118.43M | $121.69M | $64.26M | $109.24M | $101.68M | $99.64M | $58.42M | $63.00M | $72.61M | $65.09M | $62.48M | $35.60M | $30.93M | $30.18M | $27.78M | $29.37M | $29.28M |
| Low Forecast | $170.44M | $160.63M | $150.73M | $141.12M | $137.26M | $134.36M | $132.81M | $129.23M | $127.04M | $123.35M | $123.33M | $120.97M | $116.54M | $118.05M | $121.69M | $42.84M | $103.37M | $99.35M | $95.70M | $38.95M | $42.00M | $72.61M | $65.09M | $41.65M | $35.60M | $30.93M | $30.18M | $27.78M | $29.37M | $29.28M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.73% | 0.64% | 1.15% | 1.27% | 0.68% | 0.92% | 1.11% | 2.30% | 1.48% | 2.01% | 1.09% | 0.90% | 1.02% |
Lantheus's average Quarter SG&A projection for Dec 23 is $108.14M, based on 6 Wall Street analysts, with a range of $103.37M to $109.24M. The forecast indicates a 47.85% rise compared to LNTH last annual SG&A of $73.14M (Sep 23).
Lantheus EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 8 | 4 | 3 | 3 | 6 | 9 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 | 4 | 4 | 4 | 8 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.93 | $1.38 | $-0.04 | $-1.74 | $0.89 | $0.63 | $0.63 | $-0.59 | $-0.20 | $-0.39 | $0.13 | $-0.05 | $-0.10 |
| Avg Forecast | $2.14 | $2.03 | $1.90 | $1.77 | $1.97 | $1.92 | $1.92 | $1.84 | $1.96 | $1.61 | $1.67 | $1.55 | $1.53 | $1.56 | $1.83 | $1.54 | $1.43 | $1.32 | $1.31 | $1.29 | $0.96 | $0.83 | $0.70 | $0.46 | $0.17 | $0.06 | $0.05 | $-0.01 | $0.01 | $-0.06 |
| High Forecast | $2.20 | $2.09 | $1.95 | $1.82 | $2.03 | $1.98 | $1.98 | $1.90 | $2.02 | $1.66 | $1.72 | $1.57 | $1.63 | $1.57 | $1.83 | $1.56 | $1.54 | $1.35 | $1.37 | $1.36 | $0.99 | $0.83 | $0.70 | $0.46 | $0.17 | $0.06 | $0.05 | $-0.01 | $0.01 | $-0.06 |
| Low Forecast | $2.09 | $1.98 | $1.85 | $1.73 | $1.93 | $1.88 | $1.88 | $1.80 | $1.92 | $1.57 | $1.63 | $1.52 | $1.47 | $1.54 | $1.83 | $1.53 | $1.33 | $1.26 | $1.25 | $1.22 | $0.94 | $0.83 | $0.70 | $0.46 | $0.17 | $0.06 | $0.05 | $-0.01 | $0.01 | $-0.06 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.46% | 1.05% | -0.03% | -1.81% | 1.07% | 0.90% | 1.37% | -3.54% | -3.16% | -7.89% | -13.00% | -4.20% | 1.72% |
According to 6 Wall Street analysts, Lantheus's projected average Quarter EPS for Dec 23 is $1.43, with a low estimate of $1.33 and a high estimate of $1.54. This represents a -25.85% decrease compared to LNTH previous annual EPS of $1.93 (Sep 23).
Lantheus Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IRWD | Ironwood Pharmaceuticals | $3.52 | $11.67 | 231.53% | Buy |
| AQST | Aquestive Therapeutics | $4.74 | $10.25 | 116.24% | Buy |
| PCRX | Pacira BioSciences | $17.03 | $35.00 | 105.52% | Hold |
| DVAX | Dynavax | $12.17 | $24.50 | 101.31% | Buy |
| LNTH | Lantheus | $86.45 | $146.25 | 69.17% | Buy |
| AVDL | Avadel Pharmaceuticals | $10.75 | $17.80 | 65.58% | Buy |
| AMPH | Amphastar Pharmaceuticals | $44.09 | $66.00 | 49.69% | Buy |
| ANIP | ANI Pharmaceuticals | $55.10 | $79.00 | 43.38% | Buy |
| COLL | Collegium Pharmaceutical | $30.00 | $40.50 | 35.00% | Buy |
| ALKS | Alkermes | $27.91 | $36.38 | 30.35% | Hold |
| CTLT | Catalent | $59.00 | $74.25 | 25.85% | Hold |
| NBIX | Neurocrine Biosciences | $123.29 | $147.35 | 19.51% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |